Active Ingredient History
Paliperidone (9-OH-risperidone) is the primary active metabolite of the older antipsychotic risperidone. While its specific mechanism of action is unknown, it is believed that paliperidone and risperidone act via similar if not the same pathways. It has been proposed that the drug's therapeutic activity in schizophrenia is mediated through a combination of central dopamine Type 2 (D2) and serotonin Type 2 (5HT2A) receptor antagonism. Paliperidone is also active as an antagonist at alpha 1 and alpha 2 adrenergic receptors and H1 histaminergic receptors, which may explain some of the other effects of the drug. Paliperidone was approved by the FDA for treatment of schizophrenia on December 20, 2006. Very common adverse effects are: headache, tachycardia, somnolence and insomnia. NCATS
Drug Pricing (per unit)
Note: This drug pricing data is preliminary, incomplete, and may contain errors.
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
| Organization | Org Type | FDA approvals | Clinical Trials involvement | Org ID | Force Sort |
|---|
Acute Disease (Phase 4)
Amphetamine-Related Disorders (Phase 3)
Antipsychotic Agents (Phase 1)
Anxiety Disorders (Phase 3)
Autistic Disorder (Phase 3)
Bipolar Disorder (Phase 4)
Central Nervous System Depressants (Phase 1)
Central Nervous System Diseases (Phase 1)
Central Nervous System Stimulants (Phase 2/Phase 3)
Dementia (Phase 3)
Depression (Phase 3)
Depressive Disorder (Phase 1)
Depressive Disorder, Major (Phase 4)
Diabetes Mellitus (Phase 4)
Diagnosis (Phase 2/Phase 3)
Drug Therapy (Phase 2/Phase 3)
Epilepsy (Phase 1)
Healthy Volunteers (Phase 1)
Heroin Dependence (Phase 3)
Hyperprolactinemia (Phase 4)
Immunoassay (Phase 1)
Kidney Failure, Chronic (Phase 1)
Lipid Metabolism Disorders (Phase 4)
Liver Diseases (Phase 1)
Mania (Phase 3)
Mental Disorders (Phase 1)
Mental Health (Phase 4)
Methamphetamine (Phase 4)
Mood Disorders (Phase 3)
Neurotransmitter Agents (Phase 1)
Non-alcoholic Fatty Liver Disease (Phase 4)
Obsessive-Compulsive Disorder (Phase 2)
Physiological Effects of Drugs (Phase 1)
Psychomotor Agitation (Phase 4)
Psychophysiologic Disorders (Phase 3)
Psychotropic Drugs (Phase 1)
Schizophrenia, Treatment-Resistant (Phase 4)
Sexual Dysfunction, Physiological (Phase 4)
Stress Disorders, Post-Traumatic (Phase 4)
Substance Abuse, Oral (Phase 2/Phase 3)
Suicidal Ideation (Phase 4)
Tranquilizing Agents (Phase 1)
| Trial | Phase | Start Date | Organizations | Indications |
|---|
Feedback
Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).
Report issue
